Physician profile
Nicholas D Strobbe
NPI 1679808612
$37,192.80
in general payments reported to CMS, 2019-2025
33 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $71.56 · 2021: $11K · 2022: $18K · 2023: $6,614 · 2024: $366 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,828 · Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,828.25 |
| Food and Beverage | $1,868.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $28,802.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $5,475.99 | 2021-2025 | |
| Merz North America, INC. | $567.45 | 2021-2023 | Xeomin |
| Abbvie INC. | $379.69 | 2021-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $241.82 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $185.55 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $141.63 | 2019-2022 | |
| Glaxosmithkline, LLC. | $130.79 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $117.28 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.99 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $109.97 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $102.19 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $85.70 | 2019-2025 | |
| Dexcom, INC. | $78.13 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $66.16 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $59.40 | 2022 | |
| Lifescan, INC. | $55.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $48.88 | 2019-2022 | |
| Pfizer INC. | $47.96 | 2025 | |
| Abbott Laboratories | $46.91 | 2025 | Freestyle Libre 3 |
| Allergan, INC. | $39.91 | 2021-2022 | |
| Exact Sciences Corporation | $38.03 | 2024-2025 | Cologuard Collection Kit |
| Galderma Laboratories, L.P. | $36.79 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.18 | 2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $29.99 | 2023-2024 | Quviviq |
| Phadia US INC. | $28.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.21 | 2023 | Rexulti |
| Sun Pharmaceutical Industries INC. | $24.00 | 2021 | |
| Eisai INC. | $19.54 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.34 | 2023 | Horizant |
| Inogen, INC. | $16.05 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.16 | 2022 | |
| Esperion Therapeutics, INC. | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Strobbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.